Jacqueline K Phillips Selected Research

Polycystic Kidney Diseases (Polycystic Kidney Disease)

1/2022	The subfornical organ drives hypertension in polycystic kidney disease via the hypothalamic paraventricular nucleus.
1/2022	Upregulated Angiotensin Ia Receptors in the Hypothalamic Paraventricular Nucleus Sensitize Neuroendocrine Vasopressin Release and Blood Pressure in a Rodent Model of Polycystic Kidney Disease.
12/2021	Renal denervation does not affect hypertension or the renin-angiotensin system in a rodent model of juvenile-onset polycystic kidney disease: clinical implications.
1/2020	Amlodipine Improves Vessel Function and Remodeling in the Lewis Polycystic Kidney Rat Mesenteric Artery.
1/2019	Increased excitatory regulation of the hypothalamic paraventricular nucleus and circulating vasopressin results in the hypertension observed in polycystic kidney disease.
7/2017	Increased arterial stiffness does not respond to renal denervation in an animal model of secondary hypertension.
1/2016	Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease.
1/2016	Long-Term Angiotensin II Receptor Blockade Limits Hypertension, Aortic Dysfunction, and Structural Remodeling in a Rat Model of Chronic Kidney Disease.
9/2015	Progression of anemia and its relationship with renal function, blood pressure, and erythropoietin in rats with chronic kidney disease.
6/2015	The effect of losartan on differential reflex control of sympathetic nerve activity in chronic kidney disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacqueline K Phillips Research Topics

Disease

17	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2022 - 11/2011
16	Hypertension (High Blood Pressure) 01/2022 - 10/2004
7	Cysts 01/2018 - 01/2007
7	Chronic Renal Insufficiency 01/2018 - 11/2011
3	Kidney Diseases (Kidney Disease) 07/2017 - 05/2005
3	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 04/2015 - 01/2007
2	Autosomal Recessive Polycystic Kidney (Polycystic Kidney Disease, Infantile, Type I) 01/2022 - 01/2011
2	Pain (Aches) 01/2020 - 11/2014
2	Disease Progression 01/2018 - 11/2012
2	Heart Diseases (Heart Disease) 01/2016 - 04/2015
2	Hypoxia (Hypoxemia) 11/2014 - 11/2012
2	Neuralgia (Stump Neuralgia) 11/2014 - 03/2014
2	Cystic Kidney Diseases (Cystic Kidney Disease) 08/2012 - 11/2011
2	Neoplasms (Cancer) 02/2012 - 08/2006
2	Pheochromocytoma 02/2012 - 08/2006
1	Sciatic Neuropathy (Lesion of Sciatic Nerve) 01/2020
1	Tachycardia (Tachyarrhythmias) 06/2018
1	Dehydration (Water Stress) 01/2018
1	Inflammation (Inflammations) 01/2016
1	Hypertrophy 01/2016
1	Anemia 09/2015
1	Fibrosis (Cirrhosis) 04/2015
1	Proteinuria 04/2015
1	Complex Regional Pain Syndromes 11/2014
1	Reflex Sympathetic Dystrophy (Reflex Sympathetic Dystrophy Syndrome) 11/2014
1	Vascular Calcification 07/2014
1	Causalgia (Syndrome, Causalgia) 03/2014
1	Peripheral Nerve Injuries 03/2014
1	Chronic Pain 03/2014
1	Alzheimer Disease (Alzheimer's Disease) 06/2012
1	Neoplasm Metastasis (Metastasis) 02/2012

Drug/Important Bio-Agent (IBA)

5	Angiotensin IIIBA 01/2022 - 05/2005
5	CreatinineIBA 01/2016 - 01/2007
4	CatecholaminesIBA 03/2014 - 05/2005
3	Vasopressins (Vasopressin)IBA 01/2022 - 01/2018
3	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 01/2020 - 08/2006
3	Messenger RNA (mRNA)IBA 04/2015 - 05/2007
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2020 - 05/2007
2	Urethane (Ethyl Carbamate)IBA 06/2018 - 06/2011
2	Urea (Carbamide)FDA LinkGeneric 09/2015 - 01/2015
2	Proteins (Proteins, Gene)FDA Link 04/2015 - 08/2012
2	SodiumIBA 11/2014 - 05/2005
2	Adrenergic Agents (Adrenergic Drugs)IBA 03/2014 - 05/2007
2	Peptides (Polypeptides)IBA 05/2007 - 08/2006
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 05/2006 - 10/2004
2	N-Methylaspartate (NMDA)IBA 05/2006 - 10/2004
1	Pharmaceutical PreparationsIBA 01/2022
1	SaltsIBA 01/2022
1	AngiotensinsIBA 01/2022
1	Antihypertensive Agents (Antihypertensives)IBA 12/2021
1	Phenol (Carbolic Acid)FDA Link 12/2021
1	Capsaicin (Zostrix)FDA Link 12/2021
1	Saline SolutionIBA 12/2021
1	salicylhydroxamic acid (SHAM)IBA 12/2021
1	Amlodipine (Norvasc)FDA LinkGeneric 01/2020
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2020
1	Isoflurane FDA LinkGeneric 06/2018
1	Pancuronium (Pavulon)FDA LinkGeneric 06/2018
1	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2018
1	Sirolimus (Rapamycin)FDA Link 01/2016
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2016
1	Valsartan (Vals)FDA Link 01/2016
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2016
1	Matrix Metalloproteinase 9 (Gelatinase B)IBA 01/2016
1	ElastinIBA 01/2016
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	Mechanistic Target of Rapamycin Complex 2IBA 01/2016
1	Erythropoietin FDA Link 09/2015
1	Losartan (Cozaar)FDA LinkGeneric 06/2015
1	Spironolactone (Aldactone)FDA LinkGeneric 04/2015
1	AldosteroneIBA 04/2015
1	Brain Natriuretic Peptide (Natrecor)FDA Link 04/2015
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 04/2015
1	Oxygen (Dioxygen)IBA 11/2014
1	Adrenergic Receptors (Adrenergic Receptor)IBA 11/2014
1	Nicotine FDA Link 07/2014
1	Cholecalciferol (Vitamin D3)FDA Link 07/2014
1	neurofilament protein HIBA 03/2014
1	3-nitrotyrosineIBA 11/2012
1	Heme Oxygenase-1IBA 11/2012
1	Drinking WaterIBA 11/2012
1	Glucose (Dextrose)FDA LinkGeneric 11/2012
1	pimonidazoleIBA 11/2012
1	tempolIBA 11/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 11/2012
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2012
1	InterleukinsIBA 06/2012
1	hippuric acidIBA 02/2012
1	Ketoglutaric Acids (Ketoglutaric Acid)IBA 02/2012
1	Biomarkers (Surrogate Marker)IBA 02/2012
1	Dihydroxyphenylalanine (Dopa)IBA 02/2012
1	Uric Acid (Urate)IBA 02/2012
1	AllantoinIBA 02/2012
1	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA 02/2012

Therapy/Procedure

3	Denervation 01/2022 - 07/2017
2	Anesthesia 11/2014 - 04/2014
1	Therapeutics 07/2017
1	Intraperitoneal Injections 01/2016
1	Electrodes (Electrode) 11/2014
1	Ligation 03/2014